Skip to main content

Table 1 Baseline characteristics of 60 patients with new-onset polyarticular JIA

From: Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial

 

IFX+ MTX

Triple

MTX

p

Age (yrs)

10.5 (4.5—14.9)

8.2 (4.8—13.3)

10.1 (4.0—14.4)

0.06

Female (%)

14 (70)

14 (70)

11 (55)

0.21

Time (months) from disease onset

0.82 (0.0-2.7)

1.77 (0.03—7.0)

1.18 (0.03—7.1)

0.20

Rheumatoid factor positive

0

1 (5)

0

 

JIA subtype

 Polyarthritis, seronegative

19 (95)

16 (80)

15 (75)

 

 Enthesitis-related arthritis (%)

1 (5)

3 (15)

4 (20)

 

 Polyarthritis, seropositive

0

1 (5)

0

 

 Psoriatic arthritis

0

0

1 (5)

 

CHAQ

0.49 (0—1.75)

0.71 (0—2.00)

1.07 (0—1.88)

0.01

JADAS10

17.1 (6.9—23.4)

20.1 (9.8—29.8)

21.9 (11.4—30.6)

0.01

Pain-VAS

24.5 (0—90)

37.6 (4—78)

46.7 (2—85)

0.02

PhS

28.2 (21.4—35.1)

28.8 (17.9—39.6)

21.9 (12.8—30.9)

0.46

PsS

51.4 (27.1—58.5)

48.9 (37.1—62.8)

52.8 (40.2—65.8)

0.28

  1. Values are presented as mean (range), unless otherwise stated. IFX+MTX: infliximab+methrotrexate; Triple: Triple therapy of sulphasalazine, hydroxychloroquine, and methotrexate; MTX: methotrexate; CHAQ child health assessment questionnaire, JADAS juvenile arthritis disease activity score, VAS visual analoque scale, PhS Physical summary Score, PsS Psychosocial summary Score